Avoro Capital Advisors Adds $71M in Terns Pharmaceuticals, Inc. ($TERN)
Key Points
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Avoro Capital Advisors increased its position in Terns Pharmaceuticals, Inc. ($TERN) by 30.92% during the most recent quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 5,695,000 shares of Terns Pharmaceuticals, Inc. after buying 1,345,000 shares during the quarter. Avoro Capital Advisors's holdings in Terns Pharmaceuticals, Inc. were worth $301.55 million as of its most recent filing.
Terns Pharmaceuticals, Inc. Stock Holds Steady
Shares of Terns Pharmaceuticals, Inc. ($TERN) traded around $52.95 on Saturday.
Terns Pharmaceuticals, Inc. Earnings
Analysts Set New Price Targets
About Terns Pharmaceuticals, Inc.
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in Phase 1/2 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced metabolic stability and liver distribution that is in Phase IIa clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis (MASH); and TERN-801 series of small-molecule glucose-dependent insulinotropic polypeptide receptor (GIPR) modulators for obesity. The company was incorporated in 2016 and is headquartered in Foster City, California. As of May 4, 2026, Terns Pharmaceuticals, Inc. operates as a subsidiary of Merck Sharp & Dohme LLC.
Get Terns Pharmaceuticals, Inc. alerts
New 13F filings, insider trades, and analyst moves on $TERN, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.